Literature DB >> 31721301

Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer: MDSCs and immune system in Prostate cancer.

Mohammad-Javad Sanaei1, Loghman Salimzadeh2, Nader Bagheri1.   

Abstract

Prostate cancer is the second most common cancer and the fifth leading cause of cancer-associated death in men. Previous studies have revealed a surprising ability for an immature population of myeloid cells called myeloid-derived suppressor cells (MDSCs) in the commencement and development of many tumors, including those of prostate cancer. Herein, the molecular and cellular changes of MDSCs in prostate cancer in both human and nonhuman models are reviewed. The suppressive function of MDSCs are also discussed with a particular focus on the role of IL-6 and JAK/STAT3 signaling pathways in the induction of their suppressive activity. Ultimately, a brief review of MDSC-targeting approaches for potential cancer therapy is presented. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  Jak/Stat; PBMC; mCRPC

Mesh:

Year:  2019        PMID: 31721301     DOI: 10.1002/JLB.4RU0819-150RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  B7H3 expression and significance in idiopathic pulmonary fibrosis.

Authors:  Chuling Fang; Andrew E Rinke; Jing Wang; Kevin R Flaherty; Sem H Phan; Tianju Liu
Journal:  J Pathol       Date:  2021-12-22       Impact factor: 7.996

Review 2.  Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer.

Authors:  Izabela Siemińska; Jarek Baran
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

3.  Comprehensive genomic and immunophenotypic analysis of CD4 T cell infiltrating human triple-negative breast cancer.

Authors:  He Zhang; Guohui Qin; Hui Yu; Xu Han; Sha Zhu
Journal:  Cancer Immunol Immunother       Date:  2020-12-10       Impact factor: 6.968

Review 4.  Cellular immune responses in the pathophysiology of preeclampsia.

Authors:  Derek Miller; Kenichiro Motomura; Jose Galaz; Meyer Gershater; Eun D Lee; Roberto Romero; Nardhy Gomez-Lopez
Journal:  J Leukoc Biol       Date:  2021-04-13       Impact factor: 6.011

Review 5.  Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy.

Authors:  Iris Lodewijk; Sandra P Nunes; Rui Henrique; Carmen Jerónimo; Marta Dueñas; Jesús M Paramio
Journal:  Clin Epigenetics       Date:  2021-03-24       Impact factor: 6.551

6.  Interferon Regulatory Factor 4 Regulates the Development of Polymorphonuclear Myeloid-Derived Suppressor Cells Through the Transcription of c-Myc in Cancer.

Authors:  Quan Yang; Hongyan Xie; Xing Li; Yuanfa Feng; Shihao Xie; Jiale Qu; Anqi Xie; Yiqiang Zhu; Lu Zhou; Jinxue Yang; Xiaohao Hu; Haixia Wei; Huaina Qiu; Wenjuan Qin; Jun Huang
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

7.  Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.

Authors:  Sumit K Subudhi; Bilal A Siddiqui; Ana M Aparicio; Shalini S Yadav; Sreyashi Basu; Hong Chen; Sonali Jindal; Rebecca S S Tidwell; Ashwin Varma; Christopher J Logothetis; James P Allison; Paul G Corn; Padmanee Sharma
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

8.  Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer.

Authors:  Yuki Kohada; Yasuhiro Kaiho; Kazuya Takeda; Akito Kuromoto; Jun Ito; Jun Teishima; Yasuhiro Nakamura; Tomonori Kaifu; Akira Nakamura; Makoto Sato
Journal:  IJU Case Rep       Date:  2021-08-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.